Table 3.
Overall results and causes of failure
| All patients (n=102) | Non-DS de novo patients (n=78) | |
|---|---|---|
|
| ||
| Did not achieve CR | 12 (12%) | 4 (5%) |
| Refractory disease | 10 | 3 |
| Toxic death | 2 | 1 |
|
| ||
| Achieved CR | 90 (88%) | 74 (95%) |
| Died in first CR | 15 (15%) | 11 (14%) |
| Chemotherapy | 4 | 4 |
| Allogeneic HSCT | 11 | 7 |
| Autologous HSCT | 0 | 0 |
| Alive in first CR | 46 (45%) | 38 (49%) |
| Total alive | 51 (50%) | 42 (54%) |
| Relapsed | 25 (25%) | 23 (29%) |
| Chemotherapy | 14 | 13 |
| Allogeneic HSCT | 5 | 4 |
| Autologous HSCT | 6 | 6 |
| Protocol violation | 2 | 1 |
| Lineage switch | 1 | 0 |
| Increasing MRD | 1 | 1 |
|
| ||
| Causes of death | 51 (50%) | 36 (46%) |
| Leukemia | 24 | 15 |
| Infection | 16 | 11 |
| Chemotherapy | 8 | 7 |
| HSCT | 8 | 4 |
| HSCT complications | 5 | 4 |
| Other | 6 | 6 |
|
| ||
| 5-yr EFS ± 2SE | ||
| Chemotherapy | 45.9% ± 7.0% (n=61) | 51.1% ± 8.2% (n=47) |
| Allogeneic HSCT | 46.9% ± 9.1% (n=32) | 52.2% ±10.9% (n=23) |
| Autologous HSCT | 22.2% ± 11.3% (n=9) | 25.0% ± 12.5% (n=8) |
|
| ||
| 5-yr OS ± 2SE | ||
| Chemotherapy | 52.5% ± 7.4% (n=61) | 55.3% ± 8.3% (n=47) |
| Allogeneic HSCT | 46.9% ± 9.1% (n=32) | 52.2% ±10.9% (n=23) |
| Autologous HSCT | 44.4% ± 14.8% (n=9) | 50.0% ±15.8% (n=8) |